Key takeaways from the AACR Meeting 2022
Drug Target Review's Editor Victoria Rees brings you the highlights from the American Association for Cancer Research Meeting 2022.
List view / Grid view
Drug Target Review's Editor Victoria Rees brings you the highlights from the American Association for Cancer Research Meeting 2022.
The rising number of biologics approved for therapeutic use has placed an emphasis on safe and efficient production lines. Here, Drug Target Review’s Editor Victoria Rees considers why biotherapeutic development is likely to prompt significant growth for the cell line market in the next decade.
Scientists have demonstrated how automated, high-throughput life science experiments can be replicated on a modest budget.
A new report says that the global lab automation market is set to grow significantly until 2031, due to advanced drug development.
Eli Lilly scientists report that they have designed, qualified and enabled a high-throughput plasmid purification and quantification workstation.
Researchers have shown that engineered bacterial genes coding for sodium ion channels could lead to novel gene therapies for electrical heart diseases.
A new CAR T-cell therapy for B-cell cancers promises to reduce the antigen escape currently found in therapies that only target CD19.
Researchers have found that extracellular vimentin facilitates SARS-CoV-2 entry into human cells, presenting a new target.
Sanofi and Exscientia will develop up to 15 novel drug candidates by leveraging the latter's AI discovery and optimisation platform.
Researchers have found that genes in small organisms, known to extend lifespan, could also impact ageing in humans.
In mice, researchers have shown that δ-valerobetaine plays a role in neurocognitive ability, making the metabolite a target for age-related memory loss.
Researchers have developed a new drug delivery system using virus-like particles to successfully transport gene-editing proteins in pre-clinical studies.
Avacta Group announced that the chemotherapy candidate AVA3996 will be developed with a view to a first-in-human clinical trial beginning in 2023.
Using cryo-electron microscopy, researchers have completed the world’s first molecular analysis of the SARS-CoV-2 Omicron spike protein.
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza, has been exclusively licensed by Leyden Labs for development and commercialisation.